

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6142316

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ROMAIN MICOL	06/01/2020
SLAWOMIR ANTOSZCZYK	06/04/2020
RECEIVING PARTY DATA	
Name:	COMBINED THERAPEUTICS, INC.
Street Address:	251 LITTLE FALLS DRIVE
City:	WILMINGTON
State/Country:	DELAWARE
Postal Code:	19808
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	16811504
PCT Number:	US1849772
Application Number:	62632056
CORRESPONDENCE DATA	
Fax Number:	(617)832-7000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 832-1268
Email:	patentdocketing@foleyhoag.com, dmahoney@foleyhoag.com
Correspondent Name:	FOLEY HOAG LLP
Address Line 1:	155 SEAPORT BOULEVARD
Address Line 4:	BOSTON, MASSACHUSETTS 02210-2600
ATTORNEY DOCKET NUMBER:	CTJ-00101 AND 125
NAME OF SUBMITTER:	DENISE M. MAHONEY
SIGNATURE:	/Denise M. Mahoney/
DATE SIGNED:	06/08/2020
Total Attachments: 4	
source=CTJ - 160 101 125 Assignment#page1.tif	
source=CTJ - 160 101 125 Assignment#page2.tif	
source=CTJ - 160 101 125 Assignment#page3.tif	

ASSIGNMENT

WHEREAS we, Romain Micol and Slawomir Antoszczyk, have made certain inventions or discoveries (or both) set forth in the following applications for Letters Patent:

U.S. Provisional Patent Application Serial Number 62/632,056, which was filed on February 19, 2018, entitled COMPOSITIONS AND PROCESSES FOR TARGETED DELIVERY, EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS IN TISSUE; and

PCT/US2018/049772, which was filed on September 6, 2018, entitled COMPOSITIONS AND PROCESSES FOR TARGETED DELIVERY, EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS IN TISSUE; and

U.S. Patent Application Serial Number 16/811,504, which was filed on March 6, 2020, entitled COMPOSITIONS AND PROCESSES FOR TARGETED DELIVERY, EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS IN TISSUE; and

WHEREAS, Combined Therapeutics, Inc., a Delaware corporation, whose address is 251 Little Falls Drive, Wilmington, DE 19808, and which, together with its successors and assigns, is hereinafter called "Assignee," is desirous of acquiring the title, rights, benefits, and privileges hereinafter recited;

NOW, THEREFORE, for valuable consideration furnished by Assignee to us, the receipt and sufficiency of which we hereby acknowledge, we hereby, without reservation:

1. Assign, transfer, and convey to Assignee our entire right, title, and interest in and to (a) said inventions and discoveries, (b) know-how associated with said inventions and discoveries, (c) said applications for Letters Patent, (d) any and all other applications for Letters Patent setting forth said inventions and discoveries based in whole or in part upon said application, including all provisional, nonprovisional, divisional, renewal, substitute, continuation, continuation-in-part, reissue, Convention applications, International applications, national stages, regional stages, reexaminations, and extensions of Letters Patent, (e) any Letters Patent issuing from any such applications and the right to sue for past infringement thereof and for provisional rights under 35 U.S.C. § 154(d) thereof, and (f) every priority right that is or may be predicated upon or arise from any such application or any such Letters Patent;
2. Authorize Assignee to file patent applications in any or all countries on any or all of said inventions and discoveries in our names or in the name of Assignee or otherwise as Assignee may deem advisable, under the Paris Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, or otherwise;
3. Authorize and request the Director of the United States Patent and Trademark Office and equivalent authorities in all other patent offices worldwide to issue or transfer all said Letters Patent to Assignee, as assignee of the entire right, title, and interest therein or otherwise as Assignee may direct;

4. Warrant that we have not knowingly conveyed to others any right in said applications or Letters Patent or any license to said applications or Letters Patent, and that we have good right to assign the same to Assignee without encumbrance;

5. Bind our heirs, legal representatives and assigns, as well as ourselves, to do, upon Assignee's request and at Assignee's expense, but without additional consideration to us or them, all acts reasonably serving to assure that the said inventions and discoveries, said patent applications, and the said Letters Patent shall be held and enjoyed by Assignee as fully and entirely as the same could have been held and enjoyed by us, our heirs, legal representatives, and assigns if this assignment had not been made; and particularly to execute and deliver to Assignee all lawful application documents including petitions, specifications, declarations, and oaths, and all assignments, disclaimers, and lawful affidavits in form and substance as may be requested by Assignee; to communicate to Assignee all facts known to us relating to said inventions and discoveries or the history thereof; and to furnish Assignee with any and all documents, photographs, models, samples, and other physical exhibits in our control or in the control of our heirs, legal representatives or assigns which may be useful for establishing the facts of our conceptions, disclosures, and reduction to practice of said inventions and discoveries.

IN TESTIMONY OF WHICH we have executed this Assignment as an instrument under seal on the dates indicated next to our names.

June 1st 2020
Date


Romain Miron, Inventor

June 1 2020
Date


Witness

PAUL WALDRON
Witness's Printed Name

Date

Slawomir Antoszczuk, Inventor

Date

Witness

Witness's Printed Name

4. Warrant that we have not knowingly conveyed to others any right in said applications or Letters Patent or any license to said applications or Letters Patent, and that we have good right to assign the same to Assignee without encumbrance;

5. Bind our heirs, legal representatives and assigns, as well as ourselves, to do, upon Assignee's request and at Assignee's expense, but without additional consideration to us or them, all acts reasonably serving to assure that the said inventions and discoveries, said patent applications, and the said Letters Patent shall be held and enjoyed by Assignee as fully and entirely as the same could have been held and enjoyed by us, our heirs, legal representatives, and assigns if this assignment had not been made; and particularly to execute and deliver to Assignee all lawful application documents including petitions, specifications, declarations, and oaths, and all assignments, disclaimers, and lawful affidavits in form and substance as may be requested by Assignee; to communicate to Assignee all facts known to us relating to said inventions and discoveries or the history thereof; and to furnish Assignee with any and all documents, photographs, models, samples, and other physical exhibits in our control or in the control of our heirs, legal representatives or assigns which may be useful for establishing the facts of our conceptions, disclosures, and reduction to practice of said inventions and discoveries.

IN TESTIMONY OF WHICH we have executed this Assignment as an instrument under seal on the dates indicated next to our names.

Date Romain Micol, Inventor

Date Witness

Witness's Printed Name


04 June 2020
Date Sławomir Antoszczyk
Sławomir Antoszczyk, Inventor

4 June 2020
Date [Signature]
Witness

PAUL WALDRON
Witness's Printed Name

ACKNOWLEDGEMENT OF ASSIGNEE

I hereby acknowledge the foregoing executed Assignment on behalf of Combined Therapeutics, Inc.,

By: 
Date: June 4th 2020
Name: Roman Nicol
Title: CEO